103030-70-2

Basic information

• Product Name: 5-METHOXY-1,2,3,4-TETRAHYDRO-ISOQUINOLINE
• Synonyms: 5-METHOXY-1,2,3,4-TETRAHYDRO-ISOQUINOLINE;m90106;Isoquinoline, 1,2,3,4-tetrahydro-5-Methoxy-;1,2,3,4-tetrahydro-5-methoxyIsoquinoline
• CAS NO: 103030-70-2
• Molecular Formula: C₁₀H₁₃NO
• Molecular Weight: 163.219
• Mol File: 103030-70-2.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-METHOXY-1,2,3,4-TETRAHYDRO-ISOQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHOXY-1,2,3,4-TETRAHYDRO-ISOQUINOLINE(103030-70-2)
• EPA Substance Registry System: 5-METHOXY-1,2,3,4-TETRAHYDRO-ISOQUINOLINE(103030-70-2)

Safety Data

• Hazardous Substances Data: 103030-70-2(Hazardous Substances Data)

Usage

General Description

5-Methoxy-1,2,3,4-tetrahydro-isoquinoline is a chemical compound that falls under the category of tetrahydroisoquinolines, which are a group of organic compounds. The molecular formula of 5-methoxy-1,2,3,4-tetrahydro-isoquinoline is C11H15NO. 5-METHOXY-1,2,3,4-TETRAHYDRO-ISOQUINOLINE features a structure characterized by a tetrahydroisoquinoline skeleton, which is essentially an isoquinoline that has undergone hydrogenation to the point where it possesses four additional hydrogen atoms. The "5-methoxy" section of the compound's name indicates a methoxy group attached to the carbon 5 of the isoquinoline skeleton. Applications and uses of this compound may include its role in scientific research related to neurochemistry and pharmacology.

Upstream product

• 90806-58-9 5-methoxyisoquinoline 
• 53366-27-1 N-(3-methoxybenzyl)aminoacetaldehyde dimethyl acetal 
• 29969-46-8 2-formyl-1,2,3,4-tetrahydro-5-methoxyisoquinoline 
• 129075-49-6 3,4-dihydro-5-methoxy-1(2H)-isoquinolinone 
• 258882-54-1 N-(methoxycarbonyl)-2-(2-methoxyphenyl)ethylamine 
• 2045-79-6 o-methoxy-2-phenylethylamine 
• 50-00-0 formaldehyd 
• 2439-04-5 5-hydroxyisoquinoline 
• 591-31-1 3-methoxy-benzaldehyde 
• 39964-84-6 (3-Methoxy-benzylidenamino)-acetaldehyd-dimethylacetal 
• 212184-83-3 5-Methoxy-4-phenylsulfanyl-3,4-dihydro-1H-isoquinoline-2-carbaldehyde 
• 212184-76-4 N-(2-Benzenesulfinyl-ethyl)-N-(3-methoxy-benzyl)-formamide 
• 212184-93-5 N-(3-Methoxy-benzyl)-N-(2-phenylsulfanyl-ethyl)-formamide 
• 212184-89-9 (3-Methoxy-benzyl)-(2-phenylsulfanyl-ethyl)-amine 

Downstream Products

• 508236-06-4 5-(3,4-Dimethoxybenzylamino)-2-(2-furyl)-8-(5-methoxy-1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)[1,2,4]triazolo[1,5-c]pyrimidine 
• 860436-56-2 tert-butyl 5-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1394241-52-1 C₁₇H₁₇NO₅S 
• 881686-31-3 N-[(1R,4S,5S,7R)-5-(3-isopropoxyphenyl)-4-methyl-2-(3-phenylpropyl)-2-azabicyclo[3.3.1]non-7-yl]-3-(5-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)propionamide 

Relevant articles and documents

Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter

The synthesis and structure-activity relationship of a new class of indole derivatives with low-nanomolar affinity for the SERT and high selectivity versus the 5-HT1A receptor were recently reported. Based on their chemical structure, four new indolylpropylamine derivatives which contain atoms to afford future labeling with PET isotopes, were synthesized and evaluated as SERT ligands. The chemistry of these novel derivatives, their biological evaluation, the general method of preparing the precursor indole for labeling, and the C-11 labeling of the most promising indole derivative, are described herein.

UREA PEPTOID BORIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USES THEREOF

The present invention provides a urea peptidomimetic boronic compound and pharmaceutical compositions thereof, their preparative methods and uses. The compounds are represented by the following formula (I).

SAR studies of capsazepinoid bronchodilators. Part 1: The importance of the catechol moiety and aspects of the B-ring structure

Capsazepine as well as its derivatives and analogues are general inhibitors of constriction of human small airways. From a systematic variation of the capsazepine structure, divided into four regions, SARs were established. This part concerns the catechol moiety of the A-ring as well as the 2,3,4,5-tetrahydro-1H-2-azepine moiety (the B-ring) of capsazepine. It is revealed that a conformational constrain (as a fused ring) is important and that compounds with a six-membered B-ring (as a 1,2,3,4-tetrahydroisoquinoline) in general are more potent than the corresponding isoindoline, 2,3,4,5-tetrahydro-1H-2-benzazepine and 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives.